Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes

Antiviral Research

Volumn 48, Issue 2, 2000, Pages 91-99

  Shiffman, Mitchell L ^a   Verbeke, Scott B ^a   Kimball, Pamela M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle sensitivity; Hepatitis C; Immunomodulation; Interferon; Interferon receptor; Ribavirin

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2B INTERFERON; CONSENSUS INTERFERON; CYTOKINE; PHYTOHEMAGGLUTININ; RIBAVIRIN;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CELL CYCLE; CELLS, CULTURED; CYTOKINES; DRUG SYNERGISM; HUMANS; INTERFERON ALFA-2B; INTERFERON TYPE I, RECOMBINANT; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; RIBAVIRIN; T-LYMPHOCYTES;

HEPATITIS C VIRUS;

EID: 0033656846     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(00)00120-0     Document Type: Article

References (31)

1. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial
2. Comparison of 1 or 3 Mu of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis
3. The mechanisms of chronicity in hepatitis C virus infection
4. Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation
5. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial
6. Interferon alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
7. Recombinant interferon alpha therapy for chronic hepatitis C
8. Interferons in host defense
9. Clinical implication of viral quasispecies in chronic hepatitis C
10. Cytokine therapeutics: lessons from interferon a
11. The antiviral compound ribavirin modulates the T helper Th1/Th2 subset balance in hepatitis B and C virus specific immune responses
12. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients
13. Changes in cell cycling and apoptosis contribute to reduced effector cell generation among long-term heart transplant survivors
14. Sensitivity of intracellular signals responsible for cell cycle progression to cyclosporine
15. The paradox of cytokine monitoring-predictor of immunologic activity as well as immunologic silence following cardiac transplantation
16. Cytokines in viral hepatitis
17. Therapy of hepatitis C: overview
18. Recombinant human alpha interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France
19. Effects of the ribavirin interferon alfa combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients
20. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
21. Differential sensitivity of hepatitis C virus quasispecies to interferon alpha therapy
22. Expression of interferon alpha/beta receptor in the liver of chronic hepatitis C patients
23. Interferons: biological and clinical effects
24. Ribavirin inhibits viral induced macrophage production of TNF, IL1, the procoagulant fg12 prothrombinase and preserves Thl cytokine production but inhibits Th2 cytokine production
25. Molecular mechanisms of action of ribavirin
26. Interferons and their actions
27. Mechanisms of action of interferons
28. Randomized trial of interferon a2b plus ribavirin for 48 weeks or 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
29. Randomized, double-blind, placebo controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C
30. Effects of ribavirin on neutrophil function
31. Ribavirin polarizes human T-cell responses towards a type 1 cytokine profile